Samsung Epis Holdings Established to Propel Growth of Samsung Bioepis
Samsung Epis Holdings Co., Ltd. has been founded as a new investment holding company following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). The company is set to be listed on the Korea Exchange (KRX) on November 24, 2025, after creating a new subsidiary on November 14, 2025.
Samsung Bioepis will continue operating its biosimilar business as a wholly owned subsidiary of Samsung Epis Holdings.
Leadership and Vision
Kyung-Ah Kim will serve as the President and CEO of Samsung Epis Holdings while maintaining her current role as President and CEO of Samsung Bioepis.
"The new investment holding company will focus on discovering and securing investment opportunities in biotechnology for the company and its subsidiaries’ long-term growth, with scientific innovation remaining the source of our value creation. In the meantime, Samsung Bioepis will remain committed to ensuring the continued development, manufacturing, and distribution of quality-assured biosimilar medicines to patients around the world,” said Kyung-Ah Kim, President and CEO of Samsung Epis Holdings.
This strategic restructuring aims to enhance Samsung Bioepis's focus on biosimilars while expanding investment capabilities through Samsung Epis Holdings.
Would you like the author summary to be more formal or conversational?